Mergers, acquisitions and major restructurings made Big Pharma a much smaller and leaner sector, with some 54,000 jobs lost. At least that’s better than 2009’s 61,000 layoffs.
Continue reading Which Sector Lost…
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have r…
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off…
While a new report from Goldman Sachs says health care is in a state of flux that most of the sector’s companies haven’t adjusted to yet, it also pinpoints four that have plenty of cash that could be put to good use for investo…
It’s a busy day at the FDA today as panels meet to discuss two new drugs — one to help weight loss and the other to combat drug addiction — and decide whether to approve AstraZeneca’s new blood thinner medication.
…